Company intelligence / Profile preview
Tyligand Bioscience
Shanghai, Shanghai, Chinaen.tyligand.com.cn ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
First patient dosed in Phase 1/2 trial of TSN1611 (KRAS G12D inhibitor) for solid tumors in the United States as of May 2024. The program received IND clearance from U.S. FDA in February 2024 and China NMPA in April 2024.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Tyligand Bioscience.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tyligand Bioscience.